相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
Maissa Mhibik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions
Francesca Arruga et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Philipp M. Roessner et al.
LEUKEMIA (2020)
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia
Isabelle G. Solman et al.
LEUKEMIA RESEARCH (2020)
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era
Hannah R. Robinson et al.
BLOOD (2018)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
Christopher Pleyer et al.
LEUKEMIA & LYMPHOMA (2018)
Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy
Jan A. Burger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD
Samantha M. Jaglowski et al.
BLOOD ADVANCES (2018)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
Qingsong Yin et al.
JOURNAL OF IMMUNOLOGY (2017)
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
Carsten U. Niemann et al.
CLINICAL CANCER RESEARCH (2016)
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment
Elisa ten Hacken et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Marco Ruella et al.
CLINICAL CANCER RESEARCH (2016)
The molecular pathogenesis of chronic lymphocytic leukaemia
Giulia Fabbri et al.
NATURE REVIEWS CANCER (2016)
Perturbation of the normal immune system in patients with CLL
Francesco Forconi et al.
BLOOD (2015)
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib
Clare Sun et al.
BLOOD (2015)
B cells responses and cytokine production are regulated by their immune microenvironment
Monica I. Vazquez et al.
CYTOKINE (2015)
The 3 major types of innate and adaptive cell-mediated effector immunity
Francesco Annunziato et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Idit Sagiv-Barfi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Molecular Pathways: Targeting the Microenvironment in Chronic Lymphocytic Leukemia-Focus on the B-Cell Receptor
Elisa ten Hacken et al.
CLINICAL CANCER RESEARCH (2014)
Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells
Julio Gomez-Rodriguez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
John C. Riches et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Biology of Chronic Lymphocytic Leukemia in Different Microenvironments Clinical and Therapeutic Implications
Yair Herishanu et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia Potential Clinical Implications
John C. Riches et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance
Preetesh Jain et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Tec family kinases Itk and Rlk/Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates
Julio Gomez-Rodriguez et al.
FEBS JOURNAL (2011)
Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL
J. Pinon Hofbauer et al.
LEUKEMIA (2011)
T-cell function in chronic lymphocytic leukaemia
John C. Riches et al.
SEMINARS IN CANCER BIOLOGY (2010)
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages
LE Harrington et al.
NATURE IMMUNOLOGY (2005)
TEC-family kinases: Regulators of T-helper-cell differentiation
PL Schwartzberg et al.
NATURE REVIEWS IMMUNOLOGY (2005)
T-cell subsets (Th1 versus Th2)
S Romagnani
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2000)
分享论文
